Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score 5.00
- Grade N/A
- Symbol (MMX)
- Company Maverix Metals Inc.
- Price $5.00
- Changes Percentage (2.88%)
- Change $0.14
- Day Low $4.79
- Day High $5.00
- Year High $5.45
Maverix Metals Inc., together with its subsidiaries, operates as a precious metals royalty and streaming company in Canada. The company explores for gold, silver, lead, zinc, copper, nickel, and other metals. It has a portfolio of over 100 royalties and streams in the Americas and Australia. The company was incorporated in 2016 and is headquartered in Vancouver, Canada.
- Last Earnings 11/14/2022
- Ex-Dividend for 5/16 Dividend 11/29/2022
- Dividend Payable 12/15/2022
- Today N/A
- Next Earnings (Estimated) 03/14/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.17
- Trailing P/E Ratio 29.239766081871
- Forward P/E Ratio 29.239766081871
- P/E Growth 29.239766081871
- Net Income $24.07 M
Income Statement
Quarterly
Annual
Latest News of MMX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Immix Biopharma, Inc. (IMMX) Stock Price, News, Quote & History
Immix Biopharma, Inc. is a biopharmaceutical company focused on developing tissue-specific therapeutics for cancer and immune-related diseases. They are currently working on clinical trials for soft t...
By Yahoo! Finance | 3 months ago -
Immix Biopharma, Inc. (IMMX) Stock Price, News, Quote & History - Yahoo Finance
Immix Biopharma is a US-based biopharmaceutical company developing tissue-specific therapeutics for cancer and immune diseases. They are conducting clinical trials for IMX-110 and NXC-201, with a coll...
By Yahoo! Finance | 3 months ago -
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Investors are attracted to unprofitable companies like Immix Biopharma due to potential success. Analyzing cash burn, it had a cash runway of 2.2 years in March 2024. Despite growing cash burn, the co...
By Yahoo! Finance | 5 months ago
